Rafferty Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.31M | Buy |
183,024
+10,958
| +6% | +$280K | 0.02% | 438 |
|
|
2025
Q4 | $5M | Buy |
172,066
+23,771
| +16% | +$609K | 0.02% | 435 |
|
|
2025
Q3 | $2.8M | Sell |
148,295
-6,056
| -4% | -$95.5K | 0.01% | 563 |
|
|
2025
Q2 | $2.16M | Sell |
154,351
-6,016
| -4% | -$84.3K | 0.01% | 587 |
|
|
2025
Q1 | $2.51M | Sell |
160,367
-49,970
| -24% | -$704K | 0.01% | 516 |
|
|
2024
Q4 | $2.93M | Sell |
210,337
-66,481
| -24% | -$728K | 0.01% | 535 |
|
|
2024
Q3 | $2.57M | Buy |
276,818
+17,340
| +7% | +$171K | 0.01% | 574 |
|
|
2024
Q2 | $2.41M | Sell |
259,478
-562,983
| -68% | -$5.09M | 0.01% | 592 |
|
|
2024
Q1 | $8.15M | Buy |
+822,461
| New | +$6.14M | 0.03% | 342 |
|
|
2023
Q4 | – | Sell |
-419,309
| Closed | -$2.23M | – | 1075 |
|
|
2023
Q3 | $2.23M | Sell |
419,309
-80,613
| -16% | -$686K | 0.01% | 582 |
|
|
2023
Q2 | $4.76M | Buy |
499,922
+195,216
| +64% | +$2.17M | 0.03% | 425 |
|
|
2023
Q1 | $3.35M | Buy |
304,706
+1,577
| +0.5% | +$22.8K | 0.02% | 482 |
|
|
2022
Q4 | $4.49M | Buy |
303,129
+129,146
| +74% | +$2.26M | 0.04% | 393 |
|
|
2022
Q3 | $3.33M | Buy |
173,983
+131,606
| +311% | +$2.98M | 0.04% | 400 |
|
|
2022
Q2 | $903K | Sell |
42,377
-14,882
| -26% | -$305K | 0.01% | 682 |
|
|
2022
Q1 | $1.1M | Buy |
57,259
+409
| +0.7% | +$6.92K | 0.01% | 758 |
|
|
2021
Q4 | $1.18M | Buy |
56,850
+26,627
| +88% | +$530K | 0.01% | 802 |
|
|
2021
Q3 | $722K | Sell |
30,223
-7,538
| -20% | -$172K | ﹤0.01% | 957 |
|
|
2021
Q2 | $1.03M | Sell |
37,761
-3,932
| -9% | -$111K | 0.01% | 882 |
|
|
2021
Q1 | $1.21M | Buy |
41,693
+34,130
| +451% | +$1.07M | 0.01% | 730 |
|
|
2020
Q4 | $213K | Buy |
+7,563
| New | +$185K | ﹤0.01% | 974 |
|
Other funds holding ARQT
SCM
FLSM
RCMNY
PCH
VCM
GGHC
